跳至主要内容
临床试验/JPRN-UMIN000032269
JPRN-UMIN000032269已完成3 期

Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 4 With Combined Neurokinin-1 Receptor Antagonist, Palonosetron and Olanzapine in High- Emetogenic Chemotherapy - SPARED trial

St.Marianna University School of Medicine Hospital0 个研究点目标入组 281 人开始时间: 2018年4月16日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
281

研究概览

简要总结

Delayed CR rates in arm D4 and arm D1 were 79.7% and 75.0%, respectively (risk difference: -4.1%, 95% CI: -14.1% to 6.0%, P = 0.023). CR rates in arm D4 and arm D1 were 96.4% and 97.1%, (95% CI: -3.5% to 4.9%, P = 0.75) in the acute phase (0-24 h), and 79.0% and 72.8% (95% CI: -16.3% to 3.9%, P = 0.23) in the overall phase (0-120 h), respectively.

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 75years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Patients taking systemic corticosteroid (oral and intravenous) 2) Patients taking antiemetics 3) Patients who receive moderately emetogenic chemotherapy within six days before and after cisplatin administration (Minimally to low emetogenic agents are allowed) 4) Patients who receive radiation therapy to abdomen or pelvis within six days prior to enrollment until six days after cisplatin 5) Patients with symptomatic brain metastasis 6) Patients who have diabetes mellitus with use of any antidiabetic or patients with HbA1c (NGSP) >= 6.5 7) Patients who have any convulsive disorder with medication

研究者

相似试验